• Explore /
  • Poster
  • / Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.

Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.

Abstract Poster

Authors

null

Luca Gianni

IRCCS San Raffaele Hospital, Milan, Italy

Luca Gianni , Marco Colleoni , Giancarlo Bisagni , Mauro Mansutti , Claudio Zamagni , Lucia Del Mastro , Stefania Zambelli , Antonio Frassoldati , Simona Barlera , Pinuccia Valagussa , Giuseppe Viale

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT02530424

Citation

J Clin Oncol 37, 2019 (suppl; abstr 527)

DOI

10.1200/JCO.2019.37.15_suppl.527

Abstract #

527

Poster Bd #

19

Abstract Disclosures

Similar Posters

First Author: Giampaolo Bianchini

First Author: Christian F. Singer

First Author: Veronique Debien

First Author: Kelvin K H Bao